The annual fires in the United States have a high personal and financial cost.

Published Date: 08 Mar 2023

Every year, tap burns in the United States come at a high personal and financial cost, according to an analysis of nationally significant data published online in the Journal Injury Prevention.

Read Full News

Latest News

Where Have All the Leaders Gone? PAs Want to Step Up

Many PAs are well qualified for leadership roles, but organizational barriers and limited opportunities continue to stand in the way.

CMS Proposes Major Medicare Physician Payment Overhaul to Boost Primary Care

The Centers for Medicare & Medicaid Services on Tuesday proposed changes to Medicare's decades-old physician payment system, saying the ⁠updates would support the Trump...

Married to Medicine: The Other Side of the Story

Being married to a doctor isn’t the easiest job. These doctors’ spouses share what it’s like and where to get support.

Cigna Invests $100 Million in New AI-powered Specialty Pharmacy Program

Cigna said on Wednesday its health services unit Evernorth has launched a new ⁠AI-powered specialty pharmacy program to reduce the time it takes to process prescriptions and...

Resident Doctors in England Vote for UK Government's Pay Offer, Ending Strikes

Resident doctors in England have voted to accept the government's latest pay and job offer, their ⁠union said on Monday, bringing an end to a long-running industrial dispute...

Democratic-led States Sue Over Trump Administration's Medicaid Work Requirement Rule

A coalition of Democratic-led states sued on Monday to block a Trump administration rule implementing new work requirements for Medicaid recipients, ⁠arguing it unlawfully...

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Latest News

Many PAs are well qualified for leadership roles, but organizational barriers and limited opportunities continue to stand in the way.

The Centers for Medicare & Medicaid Services on Tuesday proposed changes to Medicare's decades-old physician payment system, saying the ⁠updates would support the Trump...

Being married to a doctor isn’t the easiest job. These doctors’ spouses share what it’s like and where to get support.

Cigna said on Wednesday its health services unit Evernorth has launched a new ⁠AI-powered specialty pharmacy program to reduce the time it takes to process prescriptions and...

Resident doctors in England have voted to accept the government's latest pay and job offer, their ⁠union said on Monday, bringing an end to a long-running industrial dispute...

A coalition of Democratic-led states sued on Monday to block a Trump administration rule implementing new work requirements for Medicaid recipients, ⁠arguing it unlawfully...

News All Time

What Your ZIP Code Is Costing You

Forget salary. The cities winning the physician satisfaction race are playing a completely different game.

How NPs Are Navigating Prior Authorization Coverage Barriers

The same hurdles facing physicians slow treatment for nurse practitioners’ patients, and the impact on care continues.

US FDA Issues Recall Of Boston Scientific Heart Devices

Boston Scientific has issued an urgent recall to correct several heart devices after ⁠the U.S. Food and Drug Administration classified the action as its most serious recall,...

Delays in Visa Program Threaten Hundreds of Doctors

Prolonged HHS J-1 waiver backlogs leave hundreds of foreign-trained doctors facing departure this summer, threatening care in underserved areas, immigration attorneys warn.

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Europe Risks Falling Behind in Medicine Race, Roche CEO

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

US Health Regulators to Speed Up Medicare Device Coverage

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

Germany Risks Missing Out on New Drugs, AstraZeneca CEO Says

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

U.S. to Ask States to Revalidate "high-risk" Medicaid Providers

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

US FDA Warns Medline Over Defective Heart Procedure Syringes

The U.S. Food and Drug Administration has told medical device maker Medline that its syringes used in heart procedures ⁠are defective and warned the company of penal actions.

Swiss Industry Body Says US Tariffs on Pharmaceuticals Will Harm Patients

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

The ACA Subsidy Gap and Its Toll on Primary Care

When the ACA’s subsidy credits expired at the end of 2025, physicians knew patient volume and overall revenue would tank. How are doctors faring?

Karyopharm's Drug Meets One Of Two Goals in Blood Cancer Trial

Karyopharm Therapeutics said on Tuesday its therapy led to significant reduction in spleen size in a late-stage ⁠study of patients with a rare blood cancer, meeting only one...

Match Day Traditions Are Evolving

Opening the Match Day envelope with other med students is a once-in-a-lifetime event that most students want to celebrate together, but private options are good too.

Getting The Right Signal: Does Program Signaling Work?

Designed to curb application inflation and help mid-tier candidates, signaling is now the ‘make-or-break’ metric for a match. But is it working or creating new problems?

US Proposes Easing Limits on Cancer-causing Gas Used to Clean Medical Devices

The Trump administration is proposing to lift some limits on the use of ethylene oxide, a carcinogenic gas used ⁠for sterilization, saying previous constraints imposed under...

Recommended News For You

Chromatin organization linked to p53 tumor suppression mechanism

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

There has been a new target found that might stop blood cancer.

Clinical trial sees dramatic results using radiation to treat breast cancer

An effective treatment for a rare but deadly form of cancer

Who Bears the Cost of "Forever Chemical" Cleanup?

Recommended Articles For You

Unlocking the Mystery of Ovarian Cancer Staging 

Integrative Clinical Genomics of Metastatic Cancer: Decoding Tumor Evolution for Precision Oncology 

The Benefits and Risks of Transurethral Resection of Bladder Tumor  

AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Rural-urban disparities seen in cervical cancer

2.

When does a melanoma metastasize? Implications for management

3.

Blood Test Flags Mantle Cell Lymphoma Relapse Before PET-CT

4.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

5.

New Immune Therapy Boosts Disease Control in Prostate Cancer

1.

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer

2.

ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection

3.

The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure 

4.

Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence

5.

Segmental vs. Non-Segmental Vitiligo: What’s the Difference?

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Updates on Standard V/S High Risk Myeloma Treatment

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

3.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot